Cas:15805-10-4 5,5′-methylenebis(1H-benzotriazole) manufacturer & supplier

Chemical Name:5,5′-methylenebis(1H-benzotriazole)

CAS.NO:15805-10-4

Synonyms:5,5′-methylene-bis(benzotriazole);1H-1,2,3-benzotriazole, 6,6′-methylenebis-;5,5′-methylenebis(1H-benzotriazole);Methane,bis(5-benzotriazolyl);1H-Benzotriazole,5,5′-methylenebis;Bis-(1H-benzotriazol-5-yl)-methan;2H-1,2,3-Benzotriazole, 5,5′-methylenebis-;1H-1,2,3-benzotriazole, 5,5′-methylenebis-;5,5′-Methylenebis(2H-benzotriazole);6,6′-Methylenebis(1H-benzotriazole);bis-(1H-benzotriazol-5-yl)-methane;5,5′-methylenebis-1H-Benzotriazole

Molecular Formula:C₁₃H₁₀N₆

Molecular Weight:250.259

HS Code:2933990090

Physical and Chemical Properties:

Melting point:238-240 ºC

Boiling point:543.1±60.0 °C at 760 mmHg

Density:1.502

Index of Refraction:1.819

PSA:83.14000

Exact Mass:250.096695

LogP:2.06

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5,5′-methylene-bis(benzotriazole) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5,5′-methylenebis-1H-Benzotriazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,bis-(1H-benzotriazol-5-yl)-methane Use and application,5,5′-methylene-bis(benzotriazole) technical grade,usp/ep/jp grade.

Related News: The second is known as the excipient, which is the inactive substance that serves as the vehicle for the API itself. 5,5′-methylenebis(1H-benzotriazole) manufacturer The second is known as the excipient, which is the inactive substance that serves as the vehicle for the API itself. 5,5′-methylenebis(1H-benzotriazole) supplier The second is known as the excipient, which is the inactive substance that serves as the vehicle for the API itself. 5,5′-methylenebis(1H-benzotriazole) vendor Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study. 5,5′-methylenebis(1H-benzotriazole) factory Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study.